Zhiyi Zhou1,2, Fangfang Zeng3, Jianhui Yuan2, Jinling Tang1,4, Graham A Colditz5, Shelley S Tworoger6,7, Britton Trabert8, Xuefen Su9,10. 1. Faculty of Medicine, School of Public Health and Primary Care, The Chinese University of Hong Kong, Room 508, 5/F, School of Public Health, Prince of Wales Hospital, Shatin, N.T., Hong Kong, China. 2. Shenzhen Center for Disease Control and Prevention, Shenzhen, China. 3. Guangdong Provincial Key Laboratory of Food, Nutrition and Health, School of Public Health, Sun Yat-sen University, Guangzhou, 510080, China. 4. The Chinese University of Hong Kong Shenzhen Research Institute, Shenzhen, 518057, China. 5. Alvin J. Siteman Cancer Center and Department of Surgery, Washington University School of Medicine, 660 S Euclid Ave, St Louis, MO, 63110, USA. 6. Channing Division of Network Medicine, Harvard Medical School and the Brigham and Women's Hospital, 181 Longwood Ave., 3rd Fl., Boston, MA, 02115, USA. 7. Department of Epidemiology, Harvard T. H. Chan School of Public Health, 677 Huntington Avenue, Boston, MA, 02115, USA. 8. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, NCI Shady Grove, 9609 Medical Center Drive, MSC 9774, Bethesda, MD, 20892, USA. britton.trabert@nih.gov. 9. Faculty of Medicine, School of Public Health and Primary Care, The Chinese University of Hong Kong, Room 508, 5/F, School of Public Health, Prince of Wales Hospital, Shatin, N.T., Hong Kong, China. xuefensu@cuhk.edu.hk. 10. The Chinese University of Hong Kong Shenzhen Research Institute, Shenzhen, 518057, China. xuefensu@cuhk.edu.hk.
Abstract
PURPOSE: Previous studies on pelvic inflammatory disease (PID) and the risk of ovarian cancer have found inconsistent results. We performed an updated meta-analysis to summarize the evidence of this association. METHODS: PubMed, Embase, and ISI web of science databases were searched through October 2016 for studies that investigated the PID and ovarian cancer association. Summary risk estimates were calculated using random-effects meta-analysis. RESULT: Thirteen studies were eligible for analysis, which included six cohort studies and seven case-control studies. PID was associated with an increased risk of ovarian cancer overall [relative risk (RR) 1.24, 95% CI 1.06-1.44; I 2 = 58.8%]. In analyses stratified by race, a significant positive association was observed in studies conducted among Asian women (RR 1.69, 95% CI 1.22-2.34; I 2 = 0%), but marginally significant among Caucasians (RR 1.18, 95% CI 1.00-1.39; I 2 = 60.7%).Risk estimates were elevated in both cohort (RR1.32; 95% CI 1.05-1.66; I 2 = 64.7%) and case-control studies (RR 1.17; 95% CI 0.93-1.49; I 2 = 57.6%), albeit not statistically significant in case-control studies. CONCLUSIONS: Our results suggested that PID might be a potential risk factor of ovarian cancer, with pronounced associations among Asian women. Large and well-designed studies with objective assessment methods, such as hospital records, are needed to confirm the findings of this meta-analysis.
PURPOSE: Previous studies on pelvic inflammatory disease (PID) and the risk of ovarian cancer have found inconsistent results. We performed an updated meta-analysis to summarize the evidence of this association. METHODS: PubMed, Embase, and ISI web of science databases were searched through October 2016 for studies that investigated the PID and ovarian cancer association. Summary risk estimates were calculated using random-effects meta-analysis. RESULT: Thirteen studies were eligible for analysis, which included six cohort studies and seven case-control studies. PID was associated with an increased risk of ovarian cancer overall [relative risk (RR) 1.24, 95% CI 1.06-1.44; I 2 = 58.8%]. In analyses stratified by race, a significant positive association was observed in studies conducted among Asian women (RR 1.69, 95% CI 1.22-2.34; I 2 = 0%), but marginally significant among Caucasians (RR 1.18, 95% CI 1.00-1.39; I 2 = 60.7%).Risk estimates were elevated in both cohort (RR1.32; 95% CI 1.05-1.66; I 2 = 64.7%) and case-control studies (RR 1.17; 95% CI 0.93-1.49; I 2 = 57.6%), albeit not statistically significant in case-control studies. CONCLUSIONS: Our results suggested that PID might be a potential risk factor of ovarian cancer, with pronounced associations among Asian women. Large and well-designed studies with objective assessment methods, such as hospital records, are needed to confirm the findings of this meta-analysis.
Authors: Melinda S Yates; Larissa A Meyer; Michael T Deavers; Molly S Daniels; Elizabeth R Keeler; Samuel C Mok; David M Gershenson; Karen H Lu Journal: Cancer Prev Res (Phila) Date: 2011-01-28
Authors: Christina B Rasmussen; Mette T Faber; Allan Jensen; Estrid Høgdall; Claus Høgdall; Jan Blaakær; Susanne K Kjaer Journal: Cancer Causes Control Date: 2013-04-25 Impact factor: 2.506
Authors: Christina B Rasmussen; Allan Jensen; Vanna Albieri; Klaus K Andersen; Susanne K Kjaer Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-09-26 Impact factor: 4.254
Authors: Britton Trabert; Roberta B Ness; Wei-Hsuan Lo-Ciganic; Megan A Murphy; Ellen L Goode; Elizabeth M Poole; Louise A Brinton; Penelope M Webb; Christina M Nagle; Susan J Jordan; Harvey A Risch; Mary Anne Rossing; Jennifer A Doherty; Marc T Goodman; Galina Lurie; Susanne K Kjær; Estrid Hogdall; Allan Jensen; Daniel W Cramer; Kathryn L Terry; Allison Vitonis; Elisa V Bandera; Sara Olson; Melony G King; Urmila Chandran; Hoda Anton-Culver; Argyrios Ziogas; Usha Menon; Simon A Gayther; Susan J Ramus; Aleksandra Gentry-Maharaj; Anna H Wu; Celeste Leigh Pearce; Malcolm C Pike; Andrew Berchuck; Joellen M Schildkraut; Nicolas Wentzensen Journal: J Natl Cancer Inst Date: 2014-02 Impact factor: 11.816
Authors: Britton Trabert; Tim Waterboer; Annika Idahl; Nicole Brenner; Louise A Brinton; Julia Butt; Sally B Coburn; Patricia Hartge; Katrin Hufnagel; Federica Inturrisi; Jolanta Lissowska; Alexander Mentzer; Beata Peplonska; Mark E Sherman; Gillian S Wills; Sarah C Woodhall; Michael Pawlita; Nicolas Wentzensen Journal: J Natl Cancer Inst Date: 2019-02-01 Impact factor: 13.506
Authors: Lauren C Peres; Adrianne R Mallen; Mary K Townsend; Elizabeth M Poole; Britton Trabert; Naomi E Allen; Alan A Arslan; Laure Dossus; Renée T Fortner; Inger T Gram; Patricia Hartge; Annika Idahl; Rudolf Kaaks; Marina Kvaskoff; Anthony M Magliocco; Melissa A Merritt; J Ramón Quirós; Anne Tjonneland; Antonia Trichopoulou; Rosario Tumino; Carla H van Gils; Kala Visvanathan; Nicolas Wentzensen; Anne Zeleniuch-Jacquotte; Shelley S Tworoger Journal: Cancer Res Date: 2019-08-28 Impact factor: 12.701
Authors: Katharine K Brieger; Minh Tung Phung; Bhramar Mukherjee; Kelly M Bakulski; Hoda Anton-Culver; Elisa V Bandera; David D L Bowtell; Daniel W Cramer; Anna DeFazio; Jennifer A Doherty; Sian Fereday; Renée Turzanski Fortner; Aleksandra Gentry-Maharaj; Ellen L Goode; Marc T Goodman; Holly R Harris; Keitaro Matsuo; Usha Menon; Francesmary Modugno; Kirsten B Moysich; Bo Qin; Susan J Ramus; Harvey A Risch; Mary Anne Rossing; Joellen M Schildkraut; Britton Trabert; Robert A Vierkant; Stacey J Winham; Nicolas Wentzensen; Anna H Wu; Argyrios Ziogas; Lilah Khoja; Kathleen R Cho; Karen McLean; Jean Richardson; Bronwyn Grout; Anne Chase; Cindy McKinnon Deurloo; Kunle Odunsi; Brad H Nelson; James D Brenton; Kathryn L Terry; Paul D P Pharoah; Andrew Berchuck; Gillian E Hanley; Penelope M Webb; Malcolm C Pike; Celeste Leigh Pearce Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-11-17 Impact factor: 4.090
Authors: Jennifer A Doherty; Allan Jensen; Linda E Kelemen; Celeste L Pearce; Elizabeth Poole; Joellen M Schildkraut; Kathryn L Terry; Shelley S Tworoger; Penelope M Webb; Nicolas Wentzensen Journal: J Natl Cancer Inst Date: 2017-10-01 Impact factor: 13.506
Authors: Britton Trabert; Elizabeth M Poole; Emily White; Kala Visvanathan; Hans-Olov Adami; Garnet L Anderson; Theodore M Brasky; Louise A Brinton; Renee T Fortner; Mia Gaudet; Patricia Hartge; Judith Hoffman-Bolton; Michael Jones; James V Lacey; Susanna C Larsson; Gerardo G Mackenzie; Leo J Schouten; Dale P Sandler; Katie O'Brien; Alpa V Patel; Ulrike Peters; Anna Prizment; Kim Robien; V Wendy Setiawan; Anthony Swerdlow; Piet A van den Brandt; Elisabete Weiderpass; Lynne R Wilkens; Alicja Wolk; Nicolas Wentzensen; Shelley S Tworoger Journal: J Natl Cancer Inst Date: 2019-02-01 Impact factor: 13.506